Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.

Pharmacogenetics - 1 Dec 1996

Agúndez J A, Olivera M, Ladero J M, Rodriguez-Lescure A, Ledesma M C, Diaz-Rubio M, Meyer U A, Benítez J

Abstract excerpt

The arylamine N-acetyltransferase (NAT2) is a polymorphic enzyme which is expressed in the liver in a genotype-determined manner. NAT2 is involved in activation and inactivation of carcinogens through N-acetylation. We studied the role of this polymorphism in the development of hepatocellular carcinoma (HCC). One hundred consecutive patients diagnosed for HCC and 258 healthy volunteers were studied for NAT2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Homozygote

Share to Phenotype

Share to Polymerase Chain Reaction

Source

Identifiers

PMID: 9014199
DOI: 10.1097/00008571-199612000-00003

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.PMID 9014199Read ↗

Impact of N-acetyltransferase polymorphism (NAT2) in hepatocellular carcinoma (HCC)--an investigation in a department of surgical medicine.Semantic proximity Read ↗

Joint effect of polymorphism in the N-acetyltransferase 2 gene and smoking on hepatocellular carcinoma.Semantic proximity Read ↗

Molecular mechanism of slow acetylation of drugs and carcinogens in humans.Semantic proximity Read ↗

Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population.Semantic proximity Read ↗

Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer.Semantic proximity Read ↗

Polymorphism of the N-acetyltransferase 2 gene, red meat intake, and the susceptibility of hepatocellular carcinoma.Semantic proximity Read ↗

Diverse point mutations in the human gene for polymorphic N-acetyltransferase.Semantic proximity Read ↗

Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes.Semantic proximity Read ↗

N-Acetyltransferase 2, glutathione S-transferase gene polymorphisms and susceptibility to hepatocellular carcinoma in an Algerian population.Semantic proximity Read ↗

Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk.Semantic proximity Read ↗

Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk.Semantic proximity Read ↗

Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.